OpenOnco
UA EN

Onco Wiki / Red flag

Age >75 + ECOG ≥2 OR significant comorbidity — pentostatin's weekly schedule allows finer...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDRF-HCL-FRAILTY-AGE
TypeRed flag
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesDIS-HCL
SourcesSRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025

Red Flag Origin

DefinitionAge >75 + ECOG ≥2 OR significant comorbidity — pentostatin's weekly schedule allows finer toxicity titration than cladribine 5-7 day continuous infusion; preferred for fragile patients.
Clinical directionde-escalate
Categoryfrailty-age
Shifts algorithmALGO-HCL-1L

Trigger Logic

{
  "all_of": [
    {
      "any_of": [
        {
          "comparator": ">",
          "finding": "age_years",
          "threshold": 75
        },
        {
          "comparator": ">=",
          "finding": "comorbidity_count",
          "threshold": 2
        }
      ]
    },
    {
      "comparator": ">=",
      "finding": "ecog_status",
      "threshold": 2
    }
  ],
  "type": "composite_clinical"
}

Notes

Pentostatin's weekly cadence permits adjustment between doses; cladribine's 5-7-day infusion is committed. For elderly frail, pentostatin's tolerability advantage outweighs cladribine's slightly higher CR rate.

Used By

Algorithms

Indications